Last $0.15 USD
Change Today -0.001 / -0.67%
Volume 14.8K
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

interleukin genetics inc (ILIU) Snapshot

Open
$0.14
Previous Close
$0.15
Day High
$0.15
Day Low
$0.14
52 Week High
01/13/15 - $0.46
52 Week Low
12/15/14 - $0.05
Market Cap
25.7M
Average Volume 10 Days
39.0K
EPS TTM
$-0.05
Shares Outstanding
172.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTERLEUKIN GENETICS INC (ILIU)

Related News

No related news articles were found.

interleukin genetics inc (ILIU) Related Businessweek News

No Related Businessweek News Found

interleukin genetics inc (ILIU) Details

Interleukin Genetics, Inc. focuses on the development and commercialization of personalized health products that help individuals to improve and maintain their health through preventive measures in the United States. It offers PerioPredict, a genetic test to analyze genetic variations associated with inflammation and identify individuals with risk for periodontal disease. The company also provides weight management, bone health, heart health, nutritional needs, and wellness select genetic tests under the Inherent Health brand. It is also involved in the development of osteoarthritis genetic tests for adult joint diseases. The company markets its Inherent Health brand of genetic tests through its e-commerce Website and under contract with Amway and various regional weight management focused organizations; and PST tests directly to dentists and periodontists. Interleukin Genetics, Inc. has clinical research collaborations with Stanford University, the University of North Carolina, the Mayo Clinic, Brigham & Women’s Hospital, University of California, New York University Medical Center, University of Sheffield, Yonsei University Medical Center, Tongji Medical College, Tuft’s University Medical Center, and Geisinger Clinic for the research and development of genetic tests. The company was founded in 1986 and is headquartered in Waltham, Massachusetts.

interleukin genetics inc (ILIU) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $401.4K
Interim Chief Financial Officer
Total Annual Compensation: $66.9K
Chief Marketing Officer
Total Annual Compensation: $290.8K
Compensation as of Fiscal Year 2014.

interleukin genetics inc (ILIU) Key Developments

Interleukin Genetics, Inc. Enters an Agreement with Isis Pharmaceuticals Inc

Interleukin Genetics, Inc. announced an agreement with Isis Pharmaceuticals Inc. to provide genetic testing services for Isis' Phase 2 clinical study evaluating its novel therapeutic, ISIS-APO(a)Rx, in patients with high lipoprotein(a), or Lp(a), an independent risk factor for cardiovascular disease. Patients with high levels of Lp(a) have an increased risk of atherosclerosis, coronary heart disease, aortic stenosis, heart attack and stroke. ISIS-APO(a)Rx is designed to reduce Lp(a) by inhibiting production of the apolipoprotein(a) component of Lp(a). Isis is developing ISIS-APO(a)Rx to treat patients with high Lp(a) levels who are at high risk of experiencing life-threatening cardiovascular events.

Interleukin Genetics, Inc. Presents at Brean Capital Life Sciences Summit, Nov-24-2014

Interleukin Genetics, Inc. Presents at Brean Capital Life Sciences Summit, Nov-24-2014 . Venue: Convene (Formerly Sentry Centers), 730 3rd Avenue, New York, New York, United States.

Interleukin Genetics, Inc. Announces Earnings Results for Third Quarter and Nine Months Ended September 30, 2014

Interleukin Genetics, Inc. announced earnings results for third quarter and nine months ended September 30, 2014. For the quarter, the company’s total revenue was $472,151 against $419,041 a year ago. Loss from operations was $1,457,677 against $2,167,577 a year ago. Loss from operations before income tax was $1,456,766 against $2,176,057 a year ago. Net loss was $1,456,766 against $2,176,057 a year ago. Basic and diluted net loss per common share was $0.01 against $0.02 a year ago. The increase in total revenue is primarily attributable to the addition of breakage revenue and international sales royalties in 2014 into revenues from the PerioPredict test, offset in part by a reduction in revenues from the Inherent Health product lines. For the nine months, the company reported total revenue was $1,488,312 against $1,758,562 a year ago. Loss from operations was $4,702,442 against $4,686,391 a year ago. Loss from operations before income tax was $4,697,931 against $5,153,948 a year ago. Net loss was $4,697,931 against $5,153,948 a year ago. Basic and diluted net loss per common share was $0.04 against $0.06 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILIU:US $0.15 USD -0.001

ILIU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ILIU.
View Industry Companies
 

Industry Analysis

ILIU

Industry Average

Valuation ILIU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.5x
Price/Book 19.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERLEUKIN GENETICS INC, please visit www.ilgenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.